6th May 2016 07:38
LONDON (Alliance News) - Healthcare company PureTech Health PLC on Friday said Akili Interactive Labs Inc, in which PureTech owns a 63% stake, has started open enrolment for its Attention Deficit Hyperactivity Disorder trial.
The trial will evaluate the safety and efficacy of Akili's Project: EVO platform, which aims to improve attention and neurocognition for those with cognitive disorders, in treating ADHD.
"About 75% of young children with ADHD are taking medication, yet there is a growing demand for non-pharmacological interventions. With the initiation of open enrolment for this pivotal trial, Akili is another step closer to bringing this technology from the lab of Dr Adam Gazzaley at the University of California, San Francisco, to children with ADHD," said PureTech Chief Executive Daphne Zohar.
PureTech shares were up 0.6% early Friday at 122.74 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech